Skip to content

Summit Therapeutics Inc.

SMMT

CIK 0001599298

← back to feed
Revenue (TTM)
$0
Q1 Apr 2026
Net Income (TTM)
−$1.05B
−387.8% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.40
−364.5% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$227.45M
Q1 Apr 2026
Cash
$106.52M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
776.16M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings